This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Werlen, R. C. Articles by Rose, K. Search for Related Content PubMed PubMed Citation Articles by Werlen, R. C. Articles by Rose, K.

Preparation of a Trivalent Antigen-binding Construct Using Polyoxime Chemistry: Improved Biodistribution and Potential for Therapeutic Application¹

Department of Medical Biochemistry, Centre Médical Universitaire, 1 rue Michel Servet, CH-1211 Geneva 4 [R. C. W., M. L., R. E. O., K. R.], and Division of Radiopharmacy, Paul Scherrer Institute, CH-5232 Villigen/PSI [P. A. S., A. S.], Switzerland

In an attempt to improve the pharmacokinetic behavior of an anti-tumor radioimmunoconjugate, we have prepared a trivalent antigenbinding construct formed from three Fab' fragments derived from the parent murine monoclonal antibody (MAb) 35 directed against the carcinoembryonic antigen. The construct was generated by a novel approach using polyoxime chemistry. This approach leads to a homogeneous construct, as judged by SDS-PAGE and by mass spectrometry, which was found to retain full immunoreactivity. A comparison of the monovalent, divalent, and trivalent F(ab')_n materials in vitro revealed the expected trend of increasing association constant with increasing valency. The in vivo biodistribution of the ¹²⁵I-labeled trivalent construct was studied in xenograft-bearing nude mice. Absolute tumor accumulation seen with the trivalent construct (10.8% injected dose/g) was lower than that seen with the intact MAb35 (15.2% injected dose/g). This finding and the more rapid loss of activity from tumor are presumably the consequence of the quicker blood clearance of the trivalent material. However, the construct showed tumor:blood ratios up to 10-fold higher than those seen for the parent antibody, and ratios of tumor:normal tissue accumulation were generally greatly improved. These improvements were achieved despite only modest reduction in maximum tumor accumulation when compared to the parent MAb35, and this augurs well for an improved potential for this novel construct as an agent for radioimmunotherapy and radioimmunoscintigraphy.

¹ M. L. was supported by a scholarship from the Jenny ja Antti Wihurin Rahasto (Helsinki, Finland). A. S. was supported by Schweizerische Krebsliga Grant FOR.267.92, the Gertrud Hagmann Stiftung, Lommiswil, and Krebsforschung Schweiz Grant AKT 595.

² To whom requests for reprints should be addressed.

³ Present address: Department of Virus Diagnostics, Finnish Red Cross Blood Transfusion Service. Kivihaantie 7, FIN-00310 Helsinki, Finland.

Received 9/ 8/95. Accepted 12/ 6/95.

This article has been cited by other articles:

				S. Kubetzko, E. Balic, R. Waibel, U. Zangemeister-Wittke, and A. Pluckthun PEGylation and Multimerization of the Anti-p185HER-2 Single Chain Fv Fragment 4D5: EFFECTS ON TUMOR TARGETING J. Biol. Chem., November 17, 2006; 281(46): 35186 - 35201. [Abstract] [Full Text] [PDF]

				A. Goel, S. Augustine, J. Baranowska-Kortylewicz, D. Colcher, B. J. M. Booth, G. Pavlinkova, M. Tempero, and S. K. Batra Single-Dose versus Fractionated Radioimmunotherapy of Human Colon Carcinoma Xenografts Using 131I-labeled Multivalent CC49 Single-chain Fvs Clin. Cancer Res., January 1, 2001; 7(1): 175 - 184. [Abstract] [Full Text]

				A. Goel, D. Colcher, J. Baranowska-Kortylewicz, S. Augustine, B. J. M. Booth, G. Pavlinkova, and S. K. Batra Genetically Engineered Tetravalent Single-Chain Fv of the Pancarcinoma Monoclonal Antibody CC49: Improved Biodistribution and Potential for Therapeutic Application Cancer Res., December 1, 2000; 60(24): 6964 - 6971. [Abstract] [Full Text]

				L. S. Zuckier, E. Z. Berkowitz, R. J. Sattenberg, Q. H. Zhao, H. F. Deng, and M. D. Scharff Influence of Affinity and Antigen Density on Antibody Localization in a Modifiable Tumor Targeting Model Cancer Res., December 1, 2000; 60(24): 7008 - 7013. [Abstract] [Full Text]

				J. Willuda, S. Kubetzko, R. Waibel, P. A. Schubiger, U. Zangemeister-Wittke, and A. Pluckthun Tumor Targeting of Mono-, Di-, and Tetravalent Anti-p185HER-2 Miniantibodies Multimerized by Self-associating Peptides J. Biol. Chem., April 20, 2001; 276(17): 14385 - 14392. [Abstract] [Full Text] [PDF]